Q-omics provides the consensus-scored NDUFB4P12 profile across patient tissues and cancer cell-line models. NDUFB4P12 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, NDUFB4P12 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, NDUFB4P12 protein abundance shows 8,758 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRP, COAD, and HNSC as cancer lineages where NDUFB4P12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NDUFB4P12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NDUFB4P12 survival associations across molecular data types. NDUFB4P12 RNA expression shows survival associations in the most cancer types (21), followed by mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NDUFB4P12 RNA expression–survival associations across cancer types. High NDUFB4P12 expression shows unfavorable associations in LGG, LIHC and BLCA, but favorable associations in KIRP, HNSC and KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify KIRP as the clearest survival context for NDUFB4P12 RNA expression.
This table summarizes NDUFB4P12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 4. The strongest signals are observed in BRCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for NDUFB4P12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NDUFB4P12 shows higher tumor expression in COAD, BRCA, BLCA, LUSC, KIRC and PRAD. The COAD box plot shows higher NDUFB4P12 RNA expression in tumor versus normal tissue (log2 FC = +0.268, t-test p = .021).
This table shows molecular features associated with NDUFB4P12 in patient tissues and cancer cell lines. In patient samples, NDUFB4P12 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set.
